TMPRSS2 and COVID-19: Importantly, TMPRSS2 inhibitors may not be effective in patients who are already hospitalized with COVID-19, as shown in a double-blind, randomized, placebo-controlled trial of camostat mesylate, which failed to reduce time to clinical improvement, clinical progression of the disease, or risk of death [70].